
Karyopharm Therapeutics Inc (KPTI) shares were down today as the company awaits the FDA’s decision on its Selinexor new drug application (“NDA”). The company’s stock dropped sharply on Friday, losing around 50% of its value due to FDA notes being leaked, in which the FDA voiced skepticism as to the benefit of approving the new drug in consideration of its risks. However, the agency did not reach a conclusion and voting is due to conclude by around 5 PM EST today. Here’s a recap.